These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9201256)

  • 21. Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E.
    Langhammer S; Hübner J; Kurth R; Denner J
    Immunology; 2006 Feb; 117(2):229-37. PubMed ID: 16423059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retroviruses: leukemia and immunosuppression. The Yohei Ito memorial lecture.
    Essex M
    Leukemia; 1988 Dec; 2(12 Suppl):3S-7S. PubMed ID: 2904514
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthetic hexapeptides derived from the transmembrane envelope proteins of retroviruses suppress N-formylpeptide-induced monocyte polarization.
    Oostendorp RA; Schaaper WM; Post J; Meloen RH; Scheper RJ
    J Leukoc Biol; 1992 Mar; 51(3):282-8. PubMed ID: 1541910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic peptide corresponding to a conserved domain of the retroviral protein p15E blocks IL-1-mediated signal transduction.
    Gottlieb RA; Lennarz WJ; Knowles RD; Cianciolo GJ; Dinarello CA; Lachman LB; Kleinerman ES
    J Immunol; 1989 Jun; 142(12):4321-8. PubMed ID: 2524528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human IFN-gamma production is inhibited by a synthetic peptide homologous to retroviral envelope protein.
    Ogasawara M; Cianciolo GJ; Snyderman R; Mitani M; Good RA; Day NK
    J Immunol; 1988 Jul; 141(2):614-9. PubMed ID: 2968406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppressive retroviral peptides: cAMP and cytokine patterns.
    Haraguchi S; Good RA; Day NK
    Immunol Today; 1995 Dec; 16(12):595-603. PubMed ID: 8579753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunodeficiency-inducing retroviruses.
    Joag SV; Narayan O
    Curr Opin Immunol; 1993 Aug; 5(4):595-9. PubMed ID: 8216934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The diversity of retroviral diseases of the immune system.
    O'Neill HC
    Immunol Cell Biol; 1992 Jun; 70 ( Pt 3)():193-9. PubMed ID: 1333443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human CD4+ T lymphocytes recognize a highly conserved epitope of human T lymphotropic virus type 1 (HTLV-1) env gp21 restricted by HLA DRB1*0101.
    Kitze B; Usuku K; Yamano Y; Yashiki S; Nakamura M; Fujiyoshi T; Izumo S; Osame M; Sonoda S
    Clin Exp Immunol; 1998 Feb; 111(2):278-85. PubMed ID: 9486393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tumor growth on host defenses.
    Cianciolo GJ; Snyderman R
    Cancer Metastasis Rev; 1986; 5(1):15-27. PubMed ID: 3524888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E.
    Gottlieb RA; Kleinerman ES; O'Brian CA; Tsujimoto S; Cianciolo GJ; Lennarz WJ
    J Immunol; 1990 Oct; 145(8):2566-70. PubMed ID: 2212653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIDS and the spectrum of HTLV-III/LAV infection.
    Pinching AJ; Weiss RA
    Int Rev Exp Pathol; 1986; 28():1-44. PubMed ID: 2870992
    [No Abstract]   [Full Text] [Related]  

  • 33. Suppression of lymphocyte proliferation by a retroviral p15E-derived hexapeptide.
    Oostendorp RA; Schaaper WM; Post J; Von Blomberg BM; Meloen RH; Scheper RJ
    Eur J Immunol; 1992 Jun; 22(6):1505-11. PubMed ID: 1534759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells.
    Littwitz-Salomon E; Dittmer U; Sutter K
    Retrovirology; 2016 Nov; 13(1):77. PubMed ID: 27821119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein.
    Haraguchi S; Good RA; James-Yarish M; Cianciolo GJ; Day NK
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3611-5. PubMed ID: 7724606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell receptor-derived peptides in immunoregulation and therapy of retrovirally induced immunosuppression.
    Marchalonis JJ; Robey IF; Edmundson AB; Sepulveda RT; Watson RR
    Crit Rev Immunol; 2001; 21(1-3):57-74. PubMed ID: 11642614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenesis of lentivirus infections.
    Haase AT
    Nature; 1986 Jul 10-16; 322(6075):130-6. PubMed ID: 2425264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS).
    Mosier DE; Yetter RA; Morse HC
    J Exp Med; 1987 Jun; 165(6):1737-42. PubMed ID: 3035057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a retroviral receptor used by an envelope protein derived by peptide library screening.
    Sarangi A; Bupp K; Roth MJ
    Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11032-7. PubMed ID: 17581869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Animal models for HIV infection and AIDS: memorandum from a WHO meeting.
    Bull World Health Organ; 1988; 66(5):561-74. PubMed ID: 2850118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.